Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 1/2016

Open Access 01-01-2016

Pharmacology of anticoagulants used in the treatment of venous thromboembolism

Authors: Edith A. Nutescu, Allison Burnett, John Fanikos, Sarah Spinler, Ann Wittkowsky

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2016

Login to get access

Abstract

Anticoagulant drugs are the foundation of therapy for patients with VTE. While effective therapeutic agents, anticoagulants can also result in hemorrhage and other side effects. Thus, anticoagulant therapy selection should be guided by the risks, benefits and pharmacologic characteristics of each agent for each patient. Safe use of anticoagulants requires not only an in-depth knowledge of their pharmacologic properties but also a comprehensive approach to patient management and education. This paper will summarize the key pharmacologic properties of the anticoagulant agents used in the treatment of patients with VTE.
Literature
1.
Wells PS, Forgie MA, Rodger MA (2014) Treatment of venous thromboembolism. JAMA 31(7):717–728CrossRef
2.
Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494SCrossRefPubMedPubMedCentral
3.
4.
Hirsh J, Bauer KA, Donati MB et al (2008) Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:141–159CrossRef
5.
Weitz DS, Weitz JI (2010) Update on Heparin: what do we need to know? J Thromb Thombolysis 29:199–207CrossRef
6.
7.
Bick R (2005) Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematol Oncol Clin N Am 19:1–51CrossRef
8.
Hull RD, Raskob GE, Hirsh J et al (1986) Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315:1109–1114CrossRefPubMed
9.
Raschke RA, Reilly BM, Guidry JR et al (1993) The weight-based heparin dosing nomogram compared with a “standard care” nomogram: a randomized controlled trial. Ann Intern Med 119:874–881CrossRefPubMed
10.
Rosborough TK, Shepherd MF (2004) Achieving target anti-factor Xa activity with a heparin protocol based on sex, age, height, and weight. Pharmacotherapy 24:713–719CrossRefPubMed
11.
Schulman S, Beth RJ et al (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:257–298CrossRef
12.
Crowther MA, Warkentin TE (2008) Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 111:4871–4879CrossRefPubMed
13.
Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th Ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e24S–e43SCrossRefPubMedPubMedCentral
14.
Holbrook A, Schulman S, Witt DM et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e152S–e184SCrossRefPubMedPubMedCentral
15.
Campbell NR, Hull RD, Brant R et al (1996) Aging and heparin-related bleeding. Arch Intern Med 156:857–860CrossRefPubMed
16.
17.
Douketis JD, Spyropoulos AC, Spencer FA et al (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e326S–e350SCrossRefPubMedPubMedCentral
18.
Levi M, Eerenberg E, Kamphuisen PW (2011) Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 9:1705–1712CrossRefPubMed
19.
20.
Protamine sulfate injection. AHFS Drug Information 2015. American Society of Health-System Pharmacists, Bethesda
21.
Selleng K, Warkentin TE et al (2007) Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 35(4):1165–1176CrossRefPubMed
22.
Martel N, Lee J, Wells PS et al (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710–2715CrossRefPubMed
23.
Warkentin TE, Kelton JG (2001) Temporal aspects of Heparin-induced thrombocytopenia. N Engl J Med 344:1286–1292CrossRefPubMed
24.
Warkentin TE, Greinacher A et al (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:340–380CrossRef
25.
26.
Fareed J, Hoppensteadt D, Walenga J, Igbal O, Jeske W, Sheikh T (2003) Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet 42:1043–1057CrossRefPubMed
27.
Samama MM, Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 26(Suppl 1):31–38CrossRefPubMed
28.
29.
30.
Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 43:1064–1083CrossRefPubMed
31.
Collignon F, Fryman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J et al (1995) Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin—administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 73:630–640PubMed
32.
Hasan K, Lazo-Langner A, Acedillo R, Zeller M, Hackam DG (2010) Anticoagulant response after dalteparin overdose. J Thromb Haemost 8:2321–2323CrossRefPubMed
33.
Wilson JM, Gilbert J, Harlan M, Bracey A, Allison P, Schooley C et al (2005) High-dose intravenous dalteparin can be monitored effectively using standard coagulation times. Clin Appl Thromb Hemost 11:127–138CrossRefPubMed
34.
Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H et al (2002) The pharmacokinetics of fondaparinux sodium in health volunteers. Clin Pharmacokinet 41(Suppl 2):1–9CrossRefPubMed
35.
36.
Samama MM, Guinet C (2011) Laboratory assessment of new anticoagulants. Clin Chem Lab Med 49:761–772CrossRefPubMed
37.
Smogorzewska A, Brandt JT, Chandler WL, Cunningham MT, Hayes TE et al (2006) Effect of fondaparinux on coagulation assays: results of college of American Pathologists proficiency testing. Arch Pathol Lab Med 130:1605–1611PubMed
38.
Weitz JI, Eikelboom JW, Samama MM (2012) New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e120S–e151SCrossRefPubMedPubMedCentral
39.
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th Edition. American college of chest physicians evidence-based clinical practice guidelines. Chest 141(suppl 2):e44s–e88sCrossRefPubMedPubMedCentral
40.
Ansell J, Hirsh J, Hylek E et al (2008) The pharmacology and management of the vitamin K antagonists. American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(Suppl 6):160s–198sCrossRefPubMed
41.
Stirling Y (1995) Warfarin-induced changes in procoagulant and anticoagulant proteins. Blood Coag Fibrinolysis 6:361–375CrossRef
42.
Breckenridge A, Orme M, Wessling H et al (1974) Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 15:424–430CrossRefPubMed
43.
Hignite C, Uetriecht J, Tschanz C et al (1980) Kinetics of R and S warfarin enantiomers. Clin Pharmacol Ther 28:99–105CrossRefPubMed
44.
Chan E, McLachlan AJ, Pegg M et al (1994) Disposition of warfarin enantiomers and metabolism in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 37:563–569CrossRefPubMedPubMedCentral
45.
46.
Lindh JD, Holm L, Andersson ML, Rane A (2009) Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis. Eur J Clin Pharmacol 65(4):365–375CrossRefPubMed
47.
Limdi NA, McGwin G, Goldstein JA et al (2008) Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83(2):312–321CrossRefPubMedPubMedCentral
48.
Cavallari LH, Langaee TY, Momary KM et al (2010) Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 87(4):459–464CrossRefPubMed
49.
Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadée W (2008) Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112(4):1013–1021CrossRefPubMedPubMedCentral
50.
51.
Ng VL (2009) Prothrombin time and partial thromboplastin time assay considerations. Clin Lab Med 28:253CrossRef
52.
Kirkwood TB (1983) Calibration of reference thromboplastins and standardization of the prothrombin time ratio. Thromb Haemost 49:238–244PubMed
53.
Hirsh J, Poller L (1994) The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med 154:282–288CrossRefPubMed
54.
Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K (1995) The value of plasma calibrants in correcting coagulometer effects on international normalized ratios. Am J Clin Pathol 103:358–365CrossRefPubMed
55.
Spinler SA, Nutescu ED, Smythe MA et al (2005) Anticoagulation monitoring Part 1:warfarin and parenteral direct thrombin inhibitors. Ann Pharmacother 39:1049–1055CrossRefPubMed
56.
Wittkowsky AK (2006) Drug interactions with oral anticoagulants. In: Colman RW, Marder VJ, Clowes AW et al (eds) Hemostasis and thrombosis. Basic principals and clinical practice. 5th ed. Lippincott Williams & Wilkins, Philadelphia
57.
Hansten P, Horn J (2010) Drug interactions analysis and management. Wolters Kluwer, St Louis
58.
Daly AK, Aithal GP (2003) Genetic regulation of warfarin metabolism and response. Semin Vasc Med. 3:231–237CrossRefPubMed
59.
60.
61.
62.
63.
Hellwig T, Gulseth M (2013) New oral therapies for the prevention and treatment of venous thromboembolism. AJHP 70:113–125PubMed
64.
Cabral KP (2013) Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis 36:133–140CrossRefPubMed
65.
Funk DMA (2012) Coagulation assays and anticoagulant monitoring. ASH Education Book 1:460–465
66.
Tripodi A, Siegal DM, Crowther MA, Garcia DA (2013) The laboratory and the direct oral anticoagulants. Blood 121:4032–4035CrossRefPubMed
67.
68.
Stangier J, Clemens A (2009) Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 15(Suppl 1):9S–16SCrossRefPubMed
69.
Stangier J, Rathgen K, Stähle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49:259–268CrossRefPubMed
70.
Van Ryn J, Stangier J, Haerrter S et al (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Throm Haemost 103:1116–1127CrossRef
71.
Baglin T, Hillarp A, Tripodi A et al (2013) Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. JTH 11:756–760
72.
Frost C, Nepal S, Wang J et al (2013) Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 76(5):776–786CrossRefPubMedPubMedCentral
73.
Frost C, Yu Z, Shenker A, Nepal S (2008) Food does not affect the pharmacokinetics of apixaban, an oral factor Xa inhibitor. In: Abstract presentations: IXth world conference on clinical pharmacology and therapeutics. Can J Clin Pharmacol 15:e469. July 27, 2008 to August 1, 2008, Quebec City
74.
Raghavan N, Frost C, Yu Z et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74–81CrossRefPubMed
75.
Frost C, Yu Z, Nepal S et al (2008) Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol 48:1132
76.
Frost C, Wang X, Barrett, et al. (2009) Abstracts of the XXII congress of the international society of thrombosis and haemostasis, Boston, July 2009. JTH abstract vol 7 (suppl 2): PP-MO-407
77.
Upreti VV, Wang J, Barrett YC et al (2013) Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. BJCP 76:908–916
78.
Frost C, Wang J, Li C et al (2009) Single-does safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin Pharmacol Ther 85(suppl 1):s34
79.
80.
Kubitza D, Roth A, Becka M et al (2013) Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 76:89–98CrossRefPubMedPubMedCentral
81.
82.
Becker RC, Yang H, Barrett Y et al (2011) Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban–an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 32:183–187CrossRefPubMed
83.
Bathala MS, Masumoto H, Oguma T et al (2012) Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab and Disp 40:2250–2255CrossRef
84.
Fuji T, Fujita S, Abe Y et al (2013) Evaluation of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. J Thromb Haemost 11(Suppl 2):556
85.
Parasrampuria D, Matsushima N, Chen S et al (2013) Safety, tolerability, and pharmacokinetics of edoxaban in end-stage renal disease subjects undergoing hemodialysis. J Thromb Haemost 11(Suppl 2):225
86.
Mendell J, Zahir H, Matsushima N et al (2013) Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 13(5):331–342CrossRefPubMedPubMedCentral
87.
Morishima Y, Kamisato C et al (2015) Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol 143(2):241–247CrossRefPubMed
88.
Heidbuchel H, Verhamme P, Alings M et al (2013) European Heart Rhythm Association Practical Guide on the use of new oral anti-coagulants in patients with non-valvular atrial fibrillation. Europace 15:625–651CrossRefPubMed
Metadata
Title
Pharmacology of anticoagulants used in the treatment of venous thromboembolism
Authors
Edith A. Nutescu
Allison Burnett
John Fanikos
Sarah Spinler
Ann Wittkowsky
Publication date
01-01-2016
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2016
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-015-1314-3

Other articles of this Issue 1/2016

Journal of Thrombosis and Thrombolysis 1/2016 Go to the issue

OriginalPaper

Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism

OriginalPaper

Guidance for the prevention and treatment of cancer-associated venous thromboembolism

OriginalPaper

Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism

OriginalPaper

Guidance for the treatment of deep vein thrombosis and pulmonary embolism

EditorialNotes

Management of venous thromboembolism: clinical guidance from the Anticoagulation Forum

OriginalPaper

Guidance for the evaluation and treatment of hereditary and acquired thrombophilia

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits